• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Piedmont Healthcare expands use of Glytec’s insulin dosing decision software

March 21, 2018 By Sarah Faulkner

GlytecPiedmont Healthcare, which uses Glytec‘s insulin therapy tech at three of its hospitals, plans to expand use of the eGlycemic Management System to all of its acute care facilities.

Glytec’s software features evidence-based insulin dosing decision support, surveillance of blood glucose values to identify patients at risk of low and high blood sugar, real-time alerts to warn healthcare workers of an emergency, as well as robust analytics, according to the company.

“Reducing the risks of hyperglycemia and hypoglycemia is extremely important to the health and welfare of our patients,” Dr. N. Spencer Welch, Jr., an endocrinologist at Piedmont Atlanta Hospital, said in prepared remarks. “Blood glucoses outside of the normal range can have a profound impact on patients’ recovery, length of stay, cost of care and readmission rates. Glytec’s software has been very effective in helping us maintain prescribed glucose targets, and as a result, incidence of severe hypoglycemia less than 40 mg/dL – which evidence shows is directly correlated to sentinel events – has been extremely low.”

“Expanding use of eGMS will allow Piedmont Healthcare to adopt best practices across all of its acute care facilities,” Glytec’s CMO Dr. Andrew Rhinehart added. “This translates to less variability, improved patient safety and better outcomes.”

“With eGMS, Piedmont Healthcare will have the means to demonstrate high-reliability care for patients who for reasons of diabetes or stress-induced hyperglycemia require insulin during their stay,” Glytec’s VP of clinical services, Melanie Mabrey, said.  “Use of our GlucoMetrics solution will allow us to measure progress and identify areas where improvement may be needed.”

Last month, four new studies were published in the Journal of Diabetes Science and Technology touting patient outcomes linked to Glytec’s eGlycemic diabetes management system.

In both inpatient and outpatient settings, the use of eGMS for insulin therapy management was safer and more effective than traditional standards of care. The studies reported lower rates of hypoglycemia, quicker time to target glucose levels, sustained reductions in A1c levels and faster resolution of diabetic ketoacidosis associated with Glytec’s system.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Diabetes, Drug-Device Combinations, Featured, Hospital Care, Pharmaceuticals Tagged With: Glytec

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS